Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has become one of the most prescribed medications for weight management, with clinical trials showing average weight loss of 15% over 68 weeks in adults without diabetes. However, not everyone qualifies for this therapy, and eligibility depends on several measurable factors including body mass index, cardiovascular health, and metabolic conditions. Understanding these requirements helps you determine whether semaglutide is an appropriate option for your weight loss journey.

BMI Thresholds and Weight Loss Qualification Standards

Body mass index serves as the primary screening tool for semaglutide eligibility in weight loss programs. The FDA-approved indication for weight management typically applies to adults with a BMI of 30 or higher, or those with a BMI of 27 or higher who also have at least one weight-related health condition. Your BMI is calculated by dividing your weight in kilograms by your height in meters squared, providing doctors with a standardized measure of body composition relative to height.

PlexusDx evaluates your individual BMI alongside other metabolic markers to create a personalized assessment. Some patients with lower BMI values may still qualify if they demonstrate insulin resistance, prediabetes, or cardiovascular risk factors that would benefit from semaglutide's metabolic effects. During your initial consultation, PlexusDx reviews your complete health history to ensure you meet appropriate clinical criteria for treatment initiation.

Medical History and Pre-Existing Conditions That Affect Eligibility

Your personal and family medical history plays a critical role in determining whether semaglutide is safe and appropriate for you. Certain conditions, including a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe pancreatitis, may make you ineligible for GLP-1 receptor agonists like semaglutide. PlexusDx providers conduct thorough screenings to identify any contraindications before starting treatment.

Cardiovascular health is another important consideration, as semaglutide can affect heart rate and blood pressure in some individuals. If you have a history of diabetic retinopathy, kidney disease, or gallbladder problems, your PlexusDx provider will assess whether these conditions require monitoring during treatment or make semaglutide unsuitable. Patients taking certain diabetes medications or other weight-loss drugs must also discuss potential interactions with their PlexusDx clinician.

Metabolic Testing and Blood Work Requirements for Treatment

Before starting semaglutide injection therapy, PlexusDx typically requires baseline blood work to establish your metabolic baseline and rule out contraindications. This testing includes fasting glucose levels, hemoglobin A1C to assess long-term blood sugar control, thyroid function tests, kidney and liver function markers, and lipid panels. These results help your provider confirm that semaglutide is safe for you and establish a baseline for monitoring treatment progress.

Your fasting insulin level and C-peptide measurements can reveal insulin resistance, which is an important predictor of how effectively you may respond to semaglutide therapy. PlexusDx uses this baseline data to track improvements in metabolic health beyond simple weight loss, including changes in blood sugar stability and insulin sensitivity. Regular follow-up blood work during treatment allows your provider to adjust dosing and monitor for any metabolic changes that require clinical attention.

Genetic Factors and Personalized Semaglutide Response Prediction

Individual genetic variations significantly influence how your body responds to semaglutide and other GLP-1 medications. The GLP1R rs6923761 variant affects the expression of GLP-1 receptors in your brain and pancreas, potentially influencing appetite suppression and glucose control. The GIPR rs1800437 variant relates to glucose-dependent insulinotropic peptide receptor function, which works synergistically with GLP-1 pathways to regulate satiety and metabolic rate.

PlexusDx offers the Precision Peptide Genetic Test as an add-on after your first month of treatment, which analyzes 14 peptide pathways and 150+ genetic insights to predict your individual response profile to semaglutide therapy. This test examines variants in the FTO rs9939609 gene associated with appetite regulation and the MC4R rs17782313 variant linked to energy expenditure and satiety signaling. Understanding your genetic predispositions allows PlexusDx to optimize your treatment plan and potentially switch you to alternative compounds like tirzepatide if genetic markers suggest better outcomes with dual-pathway therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum BMI required to qualify for semaglutide weight loss treatment at PlexusDx?

The standard threshold is a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as hypertension, type 2 diabetes, or sleep apnea. However, PlexusDx evaluates each patient individually based on metabolic markers, family history, and overall cardiovascular risk, so some patients with lower BMI values may qualify if they demonstrate insulin resistance or other metabolic concerns.

Can I start semaglutide if I have a history of type 2 diabetes or prediabetes?

Yes, semaglutide is actually approved for type 2 diabetes management and works effectively in patients with prediabetes or metabolic dysfunction. In fact, your prediabetes or elevated fasting glucose levels may strengthen your case for treatment eligibility. PlexusDx providers will review your glucose control history and current medication regimen to ensure safe integration of semaglutide into your treatment plan.

How much does semaglutide injection treatment cost at PlexusDx, and is it covered by insurance?

PlexusDx compounded semaglutide injection starts at $149 per month with no insurance required and no membership fees. Treatment is HSA and FSA eligible, and your dose may need to go up during titration, but your price won't increase. PlexusDx serves all 50 states and sources all medications from licensed 503A compounding pharmacies.

What medical conditions would make me ineligible for semaglutide therapy?

You would be ineligible if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe pancreatitis, as GLP-1 medications carry a theoretical risk in these populations. Uncontrolled thyroid disease, active gallbladder disease, or severe kidney disease may also require careful evaluation. PlexusDx conducts a complete medical review during your consultation to identify any absolute or relative contraindications.

How does the Precision Peptide Genetic Test help optimize my semaglutide treatment?

The PlexusDx Precision Peptide Genetic Test analyzes variants in the GLP1R, GIPR, FTO, and MC4R genes that influence your appetite regulation, glucose metabolism, and energy expenditure patterns. This test maps 14 peptide pathways and 150+ genetic insights to predict whether you'll respond optimally to semaglutide or whether a different compound like tirzepatide might produce better results for your genetic profile. The test costs $99 as an add-on after your first month of treatment.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves